Year: 2017

A lot of people find themselves in the following situation: Years pass by as life happens, you become busy, you eat whatever food comes easily, and …
Go to Source

(The Jan. 19 story corrects paragraph 9 to say Ironwood Pharma also sells Linzess in North America) (Reuters) – The U.S. Food and Drug Administration said on Thursday it had approved Synergy Pharmaceuticals Inc’s drug to treat chronic idiopathic constipation (CIC). CIC, which affects 14 percent of the global population, is a type of gastrointestinal disorder where individuals have difficult and infrequent bowel movements. Trulance met the main goals of two late-stage studies in December on irritable bowel syndrome patients with constipation (IBS-C).
Go to Source

The deal would "substantially lessen competition" in the sale of Medicare Advantage plans in 364 counties in 21 U.S. states and on the Obamacare exchange in three Florida counties, the U.S. District Court for the District of Columbia ruled on Monday. "We continue to believe a combined company will create access to higher-quality and more affordable care, and deliver a better overall experience for those we serve," Aetna Chief Executive Officer Mark Bertolini and Humana Chief Executive Offer Bruce Broussard said in a joint statement on Tuesday.

Go to Source

After the withdrawals, it was easier to make a habit of healthier eating, he said. “You get out of the routine of saturating yourself with sugar,” he said.
Go to Source

If you are looking to improve your health, the DASH diet is the way to go. For the seventh consecutive year, the DASH diet has been ranked as the best …
Go to Source

By Ginger Gibson WASHINGTON (Reuters) – The largest lobbying organization for pharmaceutical companies began running TV ads on Monday morning to improve the industry's image as criticism from U.S. President Donald Trump increases. The industry is touting developments in science by pharmaceutical companies and will spend "tens of millions" on television commercials, according to an announcement on Monday by officials of lobbying group PHRMA. Pharmaceutical companies may be facing their most difficult time ahead as criticism about the price of drugs continues to increase.

Go to Source